[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
January 14, 2004

Treatment of Sarin Exposure

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(2):181. doi:10.1001/jama.291.2.182-a

To the Editor: In his discussion of pralidoxime as an antidote to sarin, Dr Lee1 emphasized the need for slow intravenous infusion to minimize adverse effects. Although Lee described many adverse effects related to rapid infusion, the primary reason for slow administration is to prevent the muscle weakness and subsequent respiratory arrest that result from transient inhibition of cholinesterases when pralidoxime binds to the enzymes.2

First Page Preview View Large
First page PDF preview
First page PDF preview